ClinicalTrials.gg
RecruitingNCT05850962REACT-SHOCKUpdated Oct 26, 2026

Individualised Blood Pressure Targets Versus Standard Care Among Critically Ill Patients With Shock

An interventional study of Individualised MAP target in Critical Illness and Shock, sponsored by Rakshit Panwar. Recruiting at 1 site in Australia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionShockRegistry: Critical IllnessReclassifiedWhy we changed it
Registry
Critical Illness — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock
Why
  1. Critical Illness is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Shock.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Rakshit Panwar · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Oct 26, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,260
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

Aim The aim of the proposed RCT is to determine effectiveness of a strategy, where MAP (mean arterial blood pressure) targets during vasopressor therapy for shock in ICU are individualized based on patients' own pre-illness MAP that would be derived as an average of up to five most recent pre-illness blood pressure readings.

Hypothesis We hypothesize that targeting a patient's pre-illness MAP during management of shock can minimize the degree of MAP-deficit (a measure of relative hypotension), which may help reduce the risk of 14-day mortality and major adverse kidney events by day 14 in ICU.

Endpoints The primary endpoint will be the all-cause mortality rate at day 14. Secondary endpoints will be the time to death through day 14 and day 90, major adverse kidney events (MAKE-14), renal replacement therapy (RRT) free days until day 28, and 90-day all-cause mortality.

Significance To date no major RCT has tested this strategy among ICU patients with shock. This pivotal trial will provide evidence to fulfil a crucial knowledge gap regarding a common and a fundamental intervention in critical care.

02

Conditions studied

  • Critical Illness
  • Shock

Browse trials for

Keywords

  • Relative hypotension
03

In context

Shock Reclassified

487 studies on the registry are indexed under Shock; 107 are open to participants now.

This study's planned enrollment of 1,260 is above the median of 100 across 229 interventional studies indexed under Shock.

Browse Shock studies →

Lead sponsor

This is the only study on the registry with Rakshit Panwar as lead sponsor.

Compared within Shock, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ICU patients aged greater than or equal to 40 years
  • The patient is deemed to be in shock, defined as clinician-initiated vasopressor/inotropic therapy AND supported by any of the following within the last 24 hours:

    • Lactate level greater than or equal to 2 mmol/l or base deficit greater than or equal to 3 mmol/l,
    • Urine output less than or equal to 0.5 ml/kg/h or \<40 ml/h for 2 or more consecutive hours
    • Respiratory rate >22 per minute
    • Altered mentation (Glasgow Coma Score \<14)

Exclusion criteria

Exclusion Criteria:

  • Patients who are moribund, or have documented not-for-resuscitation orders
  • At least 24 hours have lapsed from the time of initiation of vasopressor or inotropic support
  • Patients who are either receiving or are deemed to imminently need renal replacement therapy.
  • Patients who already have an increase in serum creatinine of >350 µmol/l from baseline.
  • End stage renal disease
  • Patients where trauma is the main reason for the current ICU admission.
  • Previously enrolled in the REACT Shock RCT
  • Pregnancy, if known
  • Active bleeding (clinical suspicion or >2 packed red blood cells within last 24 hours)
  • Insufficient (less than two) pre-illness BP readings are available.
  • Patients on extracorporeal support (such as extracorporeal membrane oxygenation, intra-aortic balloon pump, or ventricular assist device).
  • Potential to either higher or lower BP targets (including but not limited to)

    • Cerebral perfusion pressure guided therapy e.g. intracranial hemorrhage or subarachnoid hemorrhage or traumatic brain injury
    • Abdominal perfusion pressure guided therapy
    • Aortic injury (e.g. dissection or post-operative)
    • Post cardiac surgery
    • Any other condition requiring higher or lower BP target specifically
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,260 participants (estimated)

Study arms

  • No intervention
    Standard MAP target

    The comparator or the control group will be comprised of patients assigned to standard care, where vasopressor support will be titrated to maintain a default MAP of 65 mmHg, unless the treating clinician considers a different MAP target as more appropriate.

  • Active comparator
    Individualised MAP target

    In the intervention arm, a patient's own pre-illness mean arterial pressure (MAP) would be targeted (range: 55-95 mmHg) during vasopressor support in ICU. The pre-illness MAP will be estimated from most recent pre-illness BP readings following a standardized method (Panwar et al,. Blood Press. 2017:1-9) and will be targeted for the duration of vasopressor therapy for up to a maximum of five days. The treating clinician can tailor these BP targets as deemed suitable for current clinical state. The type of vasopressor that will be used is at the discretion of the treating clinician. Study intervention will cease if a patient is considered well enough by the treating clinician for discharge out of ICU. If a patient is transported out of ICU for procedural intervention, then standard (non-study) treatment should be provided.

    Other: Individualised MAP target

Interventions

  • OtherIndividualised MAP target

    The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.

06

What researchers measure

Primary outcomes

  1. Mortality

    All deaths from randomisation to 14 days

    Time frame: 14 days

Secondary outcomes

  1. Time to death through day 14

    Time frame: First 14 days of randomisation

  2. Major Adverse Kidney Events

    Defined as a composite of death, new renal replacement therapy, or final serum creatinine level \>= 200% of the latest preillness creatinine level, as assessed from patient medical records.

    Time frame: 14 days from randomisation

  3. Renal replacement therapy free days until day 28

    Time frame: 28 days from randomisation

  4. Peak increase in serum creatinine levels

    Time frame: 28 days from randomisation

  5. Time to death through day 90

    Time frame: First 90 days of randomisation

  6. Mortality

    All deaths from randomisation to 90 days

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Panwar R. Untreated Relative Hypotension Measured as Perfusion Pressure Deficit During Management of Shock and New-Onset Acute Kidney Injury-A Literature Review. Shock. 2018 May;49(5):497-507. doi: 10.1097/SHK.0000000000001033. PubMed 29040214 ↗
  • Panwar R, Tarvade S, Lanyon N, Saxena M, Bush D, Hardie M, Attia J, Bellomo R, Van Haren F; REACT Shock Study Investigators and Research Coordinators. Relative Hypotension and Adverse Kidney-related Outcomes among Critically Ill Patients with Shock. A Multicenter, Prospective Cohort Study. Am J Respir Crit Care Med. 2020 Nov 15;202(10):1407-1418. doi: 10.1164/rccm.201912-2316OC. PubMed 32614244 ↗
  • Panwar R, Van Haren F, Cazzola F, Nourse M, Brinkerhoff G, Quail A. Standard care versus individualized blood pressure targets among critically ill patients with shock: A multicenter feasibility and preliminary efficacy study. J Crit Care. 2022 Aug;70:154052. doi: 10.1016/j.jcrc.2022.154052. Epub 2022 May 5. PubMed 35525132 ↗
  • Panwar R, Lanyon N, Davies AR, Bailey M, Pilcher D, Bellomo R. Mean perfusion pressure deficit during the initial management of shock--an observational cohort study. J Crit Care. 2013 Oct;28(5):816-24. doi: 10.1016/j.jcrc.2013.05.009. Epub 2013 Jul 10. PubMed 23849541 ↗
  • Panwar R, Sullohern B, Shiel E, Alexis Brown C, Quail A. Validity of a protocol to estimate patients' pre-morbid basal blood pressure. Blood Press. 2018 Feb;27(1):10-18. doi: 10.1080/08037051.2017.1358055. Epub 2017 Jul 26. PubMed 28745077 ↗
  • Panwar R, Gibberd A, Oldmeadow C, Tiruvoipati R, Aneman A, Kansal A; REACT SHOCK investigators. REACT SHOCK trial protocol and analysis plan-a multicenter randomised controlled trial comparing individualised blood pressure target versus standard blood pressure target among critically ill patients with shock. Trials. 2025 Oct 14;26(1):409. doi: 10.1186/s13063-025-09142-9. PubMed 41088147 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jan 2029, 66 months after the start.

Of 67 non-industry interventional studies with no phase under Shock, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 66 months is above that.

Counting every sponsor, half of 70 studies reached it within 25 months; a quarter within 8 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Jan 2028 → Jan 2029 and completion Oct 2028 → Oct 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2023
First posted
May 9, 2023
StartActual
Jul 20, 2023
Primary completionEst.
Jan 30, 2029was Jan 2028
CompletionEst.
Oct 30, 2029was Oct 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 30, 2028→Jan 30, 2029
Oct 26, 2026
Study completion
Oct 30, 2028→Oct 30, 2029
Oct 26, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41088147 ↗
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41088147 ↗
    Primary completion Jan 30, 2028→Jan 30, 2029
    Study completion Oct 30, 2028→Oct 30, 2029
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05850962
Lead sponsor
Rakshit Panwar
Responsible party
Rakshit Panwar (Conjoint Associate Professor, University of Newcastle, Australia) — Sponsor-investigator
First posted
May 9, 2023
Start date
Jul 20, 2023
Primary completion
Jan 30, 2029 (estimated)
Completion
Oct 30, 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Rakshit Panwar, PhD, MD, FCICM, MBBS
Contact
rakshitpanwar@hotmail.com
+61240420951
Flonda Probert
Contact
REACTSHOCKRCT@newcastle.edu.au

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion